*Implication for health policy/practice/research/medical education*:

Obesity, both directly and indirectly, decreases the overall lifespan in both men and women. The concept ofthe Metabolic Syndrome helps us to understand this close link between obesity, diabetes, hypertension,and renal dysfunction. More research, education and change in health policy are needed to embark to theobesity as a root causes of these problems.
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1. Context {#s1}
==========

Obesity, both directly and indirectly, increases the risk for a variety of disease conditions including diabetes, hypertension, liver disease, and certain cancers, which in turn, decreases the overall lifespan in both men and women.

2. Evidence acquisition {#s2}
=======================

Directory of Open Access Journals (DOAJ), Google Scholar, PubMed, and Web of Science were searched with keywords relevant to fat, metabolic syndrome, renal disease and kidney protection.

3. Results {#s3}
==========

The kidney has long been pondered by the minds of individuals from various professions. Scientists, artists, and philosophers alike have commented on the kidneys as a pair, as well as the ability of the body to survive with only a single kidney. In the old testament for example, the kidneys were described as organs with "fat that is upon them" and were often burned upon the altar to allow Yahweh to receive his portion ([@R01],[@R02]). By virtue of their deep location within the retroperitoneum, the kidneys were often seen as one's innermost being and self-consciousness. As many ancient cultures had seen obesity as a symbol of opulence and power, it should come to no surprise that these civilizations held the kidneys in such high regard given their close association with fat. However, in modern society obesity not only connotes laziness, but it has also been overwhelmingly proven to be detrimental to our overall health. According to the 2013 statistics from the CDC, more than 30% of adults are obese in United States ([@R03]). This is an alarming trend considering that in 1994, not a single state had an average obesity rate that exceeded 22% ([@R04]). Though the dawn of the obesity epidemic in the United States is multifactorial, it can certainly be attributed to increased consumption of high calorie foods, decreased physical activity, and the perpetuation of the belief that being overweight or obese is simply normal. Certainly the United States is not alone in this issue as even developing nations have noted similar trends, thus causing many to believe that obesity problem is on the verge of a pandemic ([@R05],[@R06]).

Obesity, both directly and indirectly, increases the risk for a variety of disease conditions including diabetes, hypertension, liver disease, and certain cancers, which in turn, decreases the overall lifespan in both men and women ([@R07]). Though the cardiovascular risks of obesity are widely acknowledged, less often identified is the relationship between obesity and renal function ([@R08]). The concept of the "Metabolic Syndrome" helps us to understand this close link between obesity, diabetes, hypertension, and renal dysfunction. From an epidemiological standpoint, the increasing rates of obesity have been subsequently followed by an increasing prevalence of diabetes ([@R04]). Moreover, the prevalence of diabetes has closely mirrored obesity in terms of geographical distribution, further highlighting this association.

The prevalence of chronic kidney disease substantially increases with the more metabolic syndrome risk factors a patient possess ([@R09]). In a review by Abrass, there are a number of pathologic links between metabolic syndrome and chronic kidney disease ([@R10]). The author highlights the relationship between hyperinsulinemia and modifications within the kidney, including glomerular hypertrophy, mesangial matrix proliferation, and glomerulosclerosis. These changes are thought to be secondary to glomerular hyperfiltration as well as inflammatory mediators from increased adiposity.

Additionally, obesity-related kidney damage has been posited to be due to hyperlipidemia, increased oxidative stress, increased salt intake, and activation of the sympathetic nervous system ([@R11]). Certainly patients with metabolic syndrome possess a number of these risk factors; however, obesity has been shown to be one of the most important independent risk factors. In both diabetic and hypertensive patients, an elevated body mass index has shown to be one of the major determinants of glomerular hyperfiltration ([@R11]-[@R13]). Elevated BMI also contributes to the development of chronic kidney disease in subjects without hypertension or diabetes ([@R14]). Interestingly, weight loss can lead to attenuation of hyperfiltration in severely obese patients, suggesting a possible therapeutic option to combat obesity-related hyperfiltration ([@R15]).

Oxidative stress secondary to increased adiposity is also thought to be a contributing factor to hyperfiltration. Li *et al.* showed that the increased GFR noted in metabolic syndrome in the swine model was preceded by activation of oxidative stress and inflammation ([@R16]). Increased oxidation of low-density lipoprotein, as observed in obese patients, stimulates synthesis of angiotensin II, which consequently increases TGF-B and plasminogen activator inhibitor-1; these inflammatory cytokines propagate glomerular fibrosis and contribute to chronic kidney disease ([@R17]).

In obese patients, cardiac output is increased to adequately maintain perfusion pressures of increased tissue mass. However, the amount of nephrons in the adult do not increase with body size, this elevated cardiac output translates into increased renal plasma flow, and in turn, increased perfusion pressure at each individual nephron ([@R12]). At the level of a single nephron, hyperfiltration is posited to precede intraglomerular hypertension which can subsequently lead to changes in efferent and afferent arteriole resistance. If these changes are allowed to persist, GFR falls progressively, leading to albuminuria and may even lead to end-stage renal failure in the long term ([@R11]).

4. Treatment strategies {#s4}
=======================

4.1. Blood pressure control {#s4-1}
---------------------------

High blood pressure is a well-known risk factor for kidney damage. Hypertension and autonomic activation have been directly associated with hyperfiltration and this effect is even more pronounced in those who are obese ([@R18],[@R19]). Okada *et al.* delineated that hyperfiltration worsened with the severity of the hypertension ([@R20]). Any patient who is hypertensive should be appropriately managed with individually catered medications and appropriate lifestyle modifications. The recommended blood pressure goal based in JNC-8 is a target systolic and diastolic blood pressure of less than 140 and 90 mmHg, respectively ([@R21]).

4.2. Inhibition of the renin-angiotensin-aldosterone axis {#s4-2}
---------------------------------------------------------

One class of antihypertensive medications that has been shown to be effective through a multitude of mechanisms is those that inhibit the renin-angiotensin-aldosterone (RAA) axis. Despite the presence of hyperfiltration, normalizing glomerular pressures could slow the rate of renal dysfunction. Within rat models, agents such as ACE inhibitors have been shown to reduce renal damage by inhibiting the RAA axis ([@R22],[@R23]). This benefit is due in part by the ability of these medications to reduce efferent arteriole pressure ([@R22]-[@R24]). Furthermore, a study has displayed that increased activation of the RAA axis is associated with inflammation, oxidative stress, hypertension, and continued worsening of the renal disease ([@R23]). Additionally, there have been marked increases in Angiotensin 1 receptors, NADPH Oxidase activity, and NFkB activation in the rodent models not receiving treatment with ACE inhibitors ([@R23]-[@R25]). Irbesartan, an angiotensin receptor blocker, was shown to reduce endothelial surface damage in rodent models ([@R25]). A further benefit of inhibition of the RAA axis, as evidenced by various trials including the LIFE, MARVAL, IDNT and RENAAL studies, have shown improvement of renal outcomes ([@R26]-[@R29]). A meta-analysis by Bakris indicates that as systolic blood pressure is lowered we witness a reduction in the rate of decline of the glomerular filtration rate ([@R30]). The Ramipril Efficacy in Nephropathy (REIN) study has shown that as serum phosphate increases, the renoprotective effects of ACE inhibitors declines; thus serum phosphate levels should be monitored if there is considerable suspicion that the therapeutic effect is being jeopardized ([@R31]).

4.3. Improve glycemic control {#s4-3}
-----------------------------

From a renal standpoint, patients with diabetes have also been shown to benefit from proper glycemic management. Uncontrolled blood sugars are proportionately related to the severity of hyperfiltration. When Okada*et al.* analyzed pre-diabetics, stage 2 pre-diabetics, and diabetics they found a progressive increase in the risk of hyperfiltration that corresponded to the severity of the diabetes ([@R20]). In a separate study, impaired fasting levels of glucose was directly correlated with hyperfiltration having accounted for confounding factors including age, sex, smoking status, body mass index, blood pressure, and insulin levels ([@R32]).

4.4. Improve dyslipidemia {#s4-4}
-------------------------

Epidemiologic evidence based on Helsinki heart study and physicians' health study showed that a higher LDL/HDL ratio is accompanied with a higher rate of decline in kidney function ([@R33],[@R34]). Several studies have shown that management of dyslipidemia has improved cardiac and stroke outcomes in those with moderate risk factors and diabetes ([@R35],[@R36]). In addition to dietary and exercise regimens, the statins have emerged as a class of medications that have shown to improve glomerular filtration. The Greace trial delineated that atorvastatin use led to increases in creatinine clearance by 12% ([@R37]). A controlled, prospective study by Bianchi*et al.* showed that statins are able to decrease proteinuria and preserve kidney function ([@R38]). Several small studies have shown that statin therapy improves the cardiovascular risk profile of persons with ESRD ([@R39]-[@R41]); however, others have detected no mortality benefit from Atorvastatin in type II diabetic dialysis patients with ESRD despite a median 42% reduction in LDL-C ([@R42]). Although, there is inconclusive evidence that use of statins in dialysis patients results in cardiovascular benefits, using statins is still a cornerstone of treatment in obesity and dyslipidemia.

4.5. Improve proteinuria {#s4-5}
------------------------

Proteinuria is a common finding in obesity. The glomerulopathy seen in obesity is pathologically similar to idiopathic focal and segmental glomerulosclerosis (FSGS), but the former has a more indolent course. The attempt to control and reduce proteinuria is still one of the goals of treatment in obese patients, although, clinical manifestation and podocyte injury is less frequent in the obese population ([@R43]). Multiple studies have been shown that ACE inhibitors and ARBs in higher doses are able to reduce proteinuria as well as control high blood pressure ([@R44],[@R45]). Aldosterone antagonists are able to decrease proteinuria and might be a good choice in the setting of obesity ([@R46]).

4.6. A potentially novel treatment {#s4-6}
----------------------------------

A newer medication that may find a place in the treatment of hyperfiltration is acetazolamide. Current clinical trials are comparing the use of furosemide with acetazolamide to investigate if prior results, which showed an 18% reduction in glomerular hyperfiltration, were due to acetazolamide or a generalized diuretic effect ([@R47],[@R48]). The proposed mechanism of acetazolamide's efficacy is through increased solute delivery to the macula densa, resulting in increased tubuloglomerular feedback, thus inhibiting glomerular filtration ([@R47]).

4.7. Lifestyle modifications {#s4-7}
----------------------------

Regardless of the numerous pharmacotherapies that exist to combat and slow down the progression of renal disease, the focus should be on the root cause: obesity. In the obese individual, the body has established a new pathological set-point. Thus, reversal of this progression is best approached through weight loss, healthier meals, and exercise that will help the body revert out of this state. This approach should be an integral part of the treatment plan for every individual ([@R13]). The entire cascade of hyperperfusion and hyperfiltration within the kidney in an obese individual can be reversed by the simple intervention of weight loss. Moreover, weight loss has the added benefit of reducing blood pressure and glucose in patients with diabetes and blood pressure ([@R10]).

Per clinical guidelines, patients who are overweight or obese should begin a regimen with an initial goal of 10% weight loss. Diet and exercise play a key role in achieving this goal. It is recommended that each individual exercise for 30 minutes per day at least 5 days per week ([@R49]). Dietary goals are equally important, but should be catered to each patient's baseline and individual needs. General guidelines encourage a low-calorie diet, which expects to reduce intake by 500 to 1,000 calories per day. Additionally, individuals should not only reduce saturated fat intake, but also grossly reduce total caloric intake of fats to 30% or less per day. Maintenance of weight loss is important, thus continued carbohydrate and fat restrictions must be followed ([@R49]). As noted by several investigations, salt intake has been shown to increase glomerular hyperfiltration, thus progressive restriction towards 100 mmol (2.3 gram) and eventually 50 mmol (1.2 grams) of salt is recommended; additionally adherence to the DASH diet is advised ([@R22],[@R50]-[@R52]). Finally, other important lifestyle changes may not be as easily recognized, but nonetheless, they can help patients with glomerular hyperfiltration. These include reducing alcohol consumption, reducing caffeine intake and discontinuing smoking ([@R13]).

5. Conclusions {#s5}
==============

Obesity-related renal injury has been posited to be due to hyperlipidemia, increased oxidative stress, increased salt intake, and activation of the sympathetic nervous system. Various treatment strategies had been suggested to decrease impact of obesity on kidneys. These are blood pressure controling, inhibition of the renin-angiotensin-aldosterone axis, improving glycemic control, improving dyslipidemia, improving proteinuria and lifestyle modifications.
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